The Relationship Between BRCA1MRNA Expression And Clinicopathological Parameters In Advanced Non-small-cell Lung Cancer And Advanced Gastric Cancer

PARTI The Relationship between BRCA1mRNA Expression and Clinicopathological Parameters in Advanced Non-small-cell Lung CancerBackground and purpose:Breast cancer susceptibility gene1(BRCA1) and receptor-associated protein80(RAP80) play important roles in chemotherapy-induced DNA damage response. The purpose of this study was to investigate whether BRCA1and RAP80mRNA expression levels were associated with clinicopathological parameters and EGFR, p53, VEGF, Her-2and COX-2protein levels in patients with stage Ⅲ-Ⅳ non-small cell lung cancer (NSCLC).Methods:The mRNA expression levels of BRCA1and RAP80were measured by real-time quantitative RT-PCR in64patients with stage Ⅲ-Ⅳ NSCLC. The relationship between the expression of BRCA1and RAP80mRNA and clinicopathological parameters were analyzed by Mann-Whitney U test, Kruskal-Wallis test and Spearman test. The correlations of the expression of BRCA1and RAP80mRNA and the expression of EGFR, VEGF, p53, Her-2and COX-2were also analyzed by these tests. Results:There was a positive correlation between BRCA1and RAP80mRNA levels (r=0.534, P<0.01). BRCA1mRNA levels were significantly higher in squamous cell carcinomas and large cell carcinoma compared with adenocarcinomas (32.4%,70.2%vs66.7%, respectively,.P=0.001). The mRNA expression of BRCA1in smokers were higher than that of non-smokers (66.7%vs40.0%, P=0.001). In patients with positive EGFR expression, the BRCA1mRNA levels were significantly lower than that of patients with negative EGFR expression (37.1%vs68.2%, P=0.014). But there were no significant differences of mRNA expressions of BRCA1according to the negative or positive protein expressions of VEGF, p53, Her-2and COX-2. RAP80mRNA levels were significantly higher in smokers than that of non-smokers (61.9%vs46.5%P=0.037). No significant differences were observed in RAP80mRNA expression levels according to the protein expressions status of EGFR, VEGF, p53, Her-2and COX-2.Conclusions:In NSCLC, the mRNA expression levels of BRCA1and RAP80were associated with history of smoking. The expression of BRCA1was different according to histology as well as EGFR protein expressions. PART2The Relationship between BRCA1mRNA Expression and Clinicopathological Parameters in Advanced Gastric CancerBackground and purpose:Breast cancer susceptibility gene1(BRCA1) plays an important role in chemotherapy-induced DNA damage response. The purpose of this study was to investigate whether BRCA1mRNA expression levels were associated with clinicopathological parameters and EGFR, p53and COX-2protein levels in patients with Advanced Gastric Cancer. Methods:The mRNA expression level of BRCA1was measured by real-time quantitative RT-PCR in131patients with stage Ⅲ-Ⅳ Gastric Cancer. The relationship between the expression of BRCA1and RAP80mRNA and clinicopathological parameters were analyzed by Mann-Whitney U test, Kruskal-Wallis test and Spearman test.The correlations of the expression of BRCA1and RAP80mRNA and the expression of EGFR, VEGF, p53, Her-2and COX-2were also analyzed by these tests.Results:The mRNA expression levels of BRCA1was not correlated with pathological type (P=0.127), lesion (P=0.536), stage of disease (P=0.377), T stage (P=0.240), N stage (P=0.235) and pathological grade (P=0.555). No significant differences were observed in BRCA1mRNA expression levels according to the protein expressions status of EGFR (P=0.673), p53(P=0.882) and COX-2(P=0.318).Conclusions:In advanced gastric cancer, the mRNA expression levels of BRCA1was not associated with Clinicopathological features as well as EGFR, p53and COX-2protein expressions.